Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 11:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 177 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Impaired Hepatic Function Clear all

Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT03902002

View directory record Official record

Conditions: Hepatic Impairment
Interventions: Omaveloxolone 50 mg capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Tustin, California • Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated May 29, 2025 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide in Participants With Impaired Liver Function

NCT03940742

View directory record Official record

Conditions: Hepatic Insufficiency
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Tustin, California • Orlando, Florida • New Orleans, Louisiana

Source: ClinicalTrials.gov public record

Updated Mar 23, 2023 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 4 Interventional

A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions

NCT00144248

View directory record Official record

Conditions: HIV Infections, Hepatic Insufficiency
Interventions: nevirapine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older

Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 5
States / cities: Bakersfield, California • San Francisco, California • Albany, New York + 1 more

Source: ClinicalTrials.gov public record

Updated Nov 30, 2023 · Synced May 21, 2026, 11:54 PM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

NCT07324616

View directory record Official record

Conditions: Hepatic Impairment (HI)
Interventions: EDG-7500; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Mar 8, 2026 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

NCT02536911

View directory record Official record

Conditions: Gaucher Disease
Interventions: eliglustat; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 79 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Miami, Florida • Knoxville, Tennessee

Source: ClinicalTrials.gov public record

Updated Feb 9, 2017 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)

NCT06444204

View directory record Official record

Conditions: Hepatic Function Abnormal, Healthy Volunteers
Interventions: Rilzabrutinib; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Jun 4, 2024 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age

NCT06222892

View directory record Official record

Conditions: Cough
Interventions: Camlipixant; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Jan 6, 2026 · Synced May 21, 2026, 11:54 PM EDT

Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

NCT07036133

View directory record Official record

Conditions: Advanced Solid Tumors, Hematologic Malignancies
Interventions: Pralatrexate Injection; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Cerritos, California • Chicago, Illinois • Detroit, Michigan + 1 more

Source: ClinicalTrials.gov public record

Updated Feb 10, 2026 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

NCT02421042

View directory record Official record

Conditions: Hepatic Impairment, Hepatic Function
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Source: ClinicalTrials.gov public record

Updated May 4, 2015 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

NCT05724693

View directory record Official record

Conditions: Healthy Volunteer, Hepatic Impairment
Interventions: Bemnifosbuvir (BEM); Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Jul 30, 2024 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

NCT02412098

View directory record Official record

Conditions: Long QT Syndrome
Interventions: Eleclazine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Source: ClinicalTrials.gov public record

Updated Jul 28, 2019 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function

NCT05765344

View directory record Official record

Conditions: Hepatic Impairment, Healthy
Interventions: Bulevirtide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 79 Years

Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Lake Forest, California • Miami, Florida • Orlando, Florida + 1 more

Source: ClinicalTrials.gov public record

Updated Jan 25, 2026 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

NCT05481411

View directory record Official record

Conditions: Hepatic Impairment
Interventions: Olpasiran; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Rialto, California • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Oct 14, 2025 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects

NCT01299454

View directory record Official record

Conditions: Schizophrenia
Interventions: OPC-34712; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Miami, Florida • Minneapolis, Minnesota • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Oct 19, 2015 · Synced May 21, 2026, 11:54 PM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT06911320

View directory record Official record

Conditions: Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Interventions: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination; Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Source: ClinicalTrials.gov public record

Updated Apr 12, 2026 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT04454424

View directory record Official record

Conditions: Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions: BAY1817080, Midazolam; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years

Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Jan 19, 2023 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function

NCT03040479

View directory record Official record

Conditions: Migraine
Interventions: lasmiditan 200 mg; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Kentucky

Source: ClinicalTrials.gov public record

Updated Nov 26, 2019 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

NCT02397707

View directory record Official record

Conditions: HCV Infection
Interventions: Voxilaprevir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Apr 8, 2020 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Results available

Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients

NCT03359850

View directory record Official record

Conditions: Ovarian Neoplasms, Neoplasms, Solid Tumor, Hepatic Impairment
Interventions: Niraparib; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Los Angeles, California • Newport Beach, California • Aurora, Colorado + 2 more

Source: ClinicalTrials.gov public record

Updated May 27, 2021 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

NCT04823702

View directory record Official record

Conditions: Impaired Hepatic Function
Interventions: Aldafermin; Biological
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Jan 18, 2022 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

NCT05404529

View directory record Official record

Conditions: Hepatic Impairment
Interventions: Tavapadon; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated May 29, 2023 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function

NCT01732263

View directory record Official record

Conditions: Hepatic Impairment, Healthy
Interventions: SSP-004184; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Jul 18, 2021 · Synced May 21, 2026, 11:54 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

NCT01817985

View directory record Official record

Conditions: Chronic Hepatitis C
Interventions: GS-5816; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years

Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 5
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Aug 28, 2013 · Synced May 21, 2026, 11:54 PM EDT

Terminated Phase 1 Interventional

Study of ALXN2050 in Participants With Hepatic Impairment

NCT05259085

View directory record Official record

Conditions: Impaired Hepatic Function, Healthy
Interventions: ALXN2050; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed

Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Mar 18, 2025 · Synced May 21, 2026, 11:54 PM EDT